First EU Centralized Switch Goes To Alli, Could Spark More Applications
This article was originally published in The Pink Sheet Daily
Executive Summary
Central process will doubtless attract other switches, but countries will determine whether drug is still sold from pharmacies.
You may also be interested in...
GlaxoSmithKline Looks To Revamp U.S. Operations In Tough Environment
U.S. sales fell 13 percent in the third quarter due to generic competition and Avandia.
EU Shifts To Centralized OTC Process At Member States’ Expense – GSK Exec
Europe's development of a centralized process for approving nonprescription pharmaceuticals is sapping the resources of the regulatory agencies of European Union member states, a GlaxoSmithKline regulatory executive says
Behavioral Science Banner Maps The Future Of GSK Consumer Business
Roger Scarlett-Smith, the new head of GlaxoSmithKline's North American Consumer Healthcare business, believes a nonprescription statin is probably inevitable in the U.S., and his firm still wants to be in early on that opportunity